Ann: Company Presentation - Investor Insights, page-70

Refer the companies response to asx compliance..and look at COV today!!!

BDX and its technology are focussed on breast cancer testing, however BDX notes that the share price for
CLEO Diagnostics Limited (ASX:COV), a company whose ovarian cancer blood test is often grouped with
BDX from the perspective of “women’s health diagnostics” increased ~41% on 29 May 2024 following its
announcement of COV’s latest benchmarking study. It is unclear whether this is linked to an impact on the
price of BDX shares.

While BDX has not experienced this reaction previously in relation to its regular investor awareness meetings,
BDX’s Chair and Chief Executive Officer hosted investor awareness meetings in Melbourne, Sydney and
Brisbane last week to raise community awareness of the information publicly available via ASX. As BDX is not
yet able to identify the recent purchasers, it can only speculate as to whether those purchasers might include
attendees at those investor awareness meetings, who may have more closely considered the information
BDX has disclosed via ASX, including but not limited to BDX’s focus on its targeted commercial release for its
blood-based biomarker test for breast cancer before the end of calendar 2024.

BDX’s shareholder newsletter circulated at around 9.57am on 29 May 2024 drew shareholder attention to the
information included in its latest Quarterly Activities/Appendix 4C Cash Flow Report. That document did not
include any information that has not been announced to the market which, if known by some in the market,
could explain the recent trading in its securities.